CGEN Compugen Ltd.

-0.15  -4%
Previous Close 3.61
Open 3.57
Price To Book 6.18
Market Cap 207,261,515
Shares 59,902,172
Volume 76,430
Short Ratio
Av. Daily Volume 132,421

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 enrolment in monotherapy dose escalation arm to be completed 3Q 2019.
Solid tumors
Phase 1 trial initiated September 2018.
BAY 1905254
Solid tumors

Latest News

  1. Compugen Appoints Eran Perry to Its Board of Directors
  2. How Many Compugen Ltd. (NASDAQ:CGEN) Shares Do Institutions Own?
  3. Do Institutions Own Shares In Compugen Ltd. (NASDAQ:CGEN)?
  4. Compugen (CGEN) Upgraded to Strong Buy: Here's What You Should Know
  5. Compugen Presents Update on COM701 Phase 1 Trial at the 2019 ASCO Annual Meeting
  6. Compugen (CGEN) Upgraded to Buy: Here's What You Should Know
  7. Compugen to Present at the Jefferies 2019 Healthcare Conference
  8. Stocks Close Lower on Monday
  9. Compugen Ltd. (CGEN) Q1 2019 Earnings Call Transcript
  10. Compugen: 1Q Earnings Snapshot
  11. Compugen Reports First Quarter 2019 Results
  12. Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors
  13. Compugen First Quarter 2019 Conference Call Scheduled for Monday, May 20, 2019 at 8:30 AM ET
  14. What Makes Compugen (CGEN) a New Strong Buy Stock
  15. Compugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting
  16. Chinese Regulatory Authority Approves IND Application of Oramed's Oral Insulin Capsules
  17. Compugen Announces Purchase of Company Shares by its Board of Directors and Members of Management
  18. Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate
  19. Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4
  20. Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?